News | June 14, 2024
Devyser launches updated Y-Chromosomal microdeletion test
Find out more
Admin (2)
Devyser wins tender for oncology NGS solutions in Italy
Devyser wins tender for thalassemia in Italy
Devyser Diagnostics AB publishes quarterly report for the period January to March 2024
Devyser receives IVDR approval for post-transplant monitoring software
Devyser partners with Hamilton to automate laboratory NGS workflows
Devyser receives MDSAP certification for Brazil
Devyser publishes annual report for 2023
Devyser´s annual report 2023 has today been published on the company´s website. The report is...
Devyser CFTR 68 provides NHS Scotland with trustworthy, rapid results
We spoke with Dr. Andrew Purvis, Clinical Scientist for West of Scotland Centre for Genomic...
Devyser achieves breakthrough in the US with cystic fibrosis NGS test
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is...
2023: A year in studies
2023 was an excellent year for Devyser, and a range of our products appeared in scientific journals...
Devyser announces study publication demonstrating dd-cfDNA detection in dual donor kidney transplant patients
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...